How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches
Despite extensive research efforts, advanced gastric cancer still has a dismal prognosis with conventional treatment options. Immune checkpoint inhibitors have revolutionized the treatment landscape for many solid tumors. Amongst gastric cancer subtypes, tumors with microsatellite instability and Ep...
Main Authors: | Michele Ghidini, Angelica Petrillo, Andrea Botticelli, Dario Trapani, Alessandro Parisi, Anna La Salvia, Elham Sajjadi, Roberto Piciotti, Nicola Fusco, Shelize Khakoo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/7/1412 |
Similar Items
-
Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities
by: Roberto Piciotti, et al.
Published: (2021-04-01) -
Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer
by: Hung-Yuan Yu, et al.
Published: (2022-01-01) -
EBV and MSI Status in Gastric Cancer: Does It Matter?
by: Catarina Neto do Nascimento, et al.
Published: (2022-12-01) -
KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer
by: Chunhua Ni, et al.
Published: (2024-04-01) -
Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer
by: Na Yang, et al.
Published: (2021-05-01)